New Data Show Early Initiation of Ocrelizumab Improves MS Outcomes

New 5-year data from open-label extensions of the OPERA I, OPERA II, and ORATORIO phase 3 studies show that patients treated earlier with ocrelizumab (Ocrevus) had better outcomes on multiple measures of multiple sclerosis disease activity.

The data will be presented at the 34th Congress of the European Committee for the Treatment and Research in Multiple Sclerosis (ECTRIMS) from October 10-12 in Berlin, Germany.

“The new data presented at ECTRIMS demonstrate that Ocrevus’ efficacy continued over five years in relapsing and primary progressive MS, and notably, include the largest body of evidence for any medicine to significantly slow disability progression in primary progressive MS,” said Stephen Hauser, MD, chair of the Scientific Steering Committee of the OPERA studies, professor of neurology at the University of California, San Francisco, and director of the UCSF Weill Institute for Neurosciences. “The data also suggest that Ocrevus rapidly suppressed relapse and MRI disease activity in people with relapsing MS who switched from interferon beta-1α, and additionally, that earlier treatment with Ocrevus reduced disability progression and brain atrophy.”

In extensions of the OPERA I and OPERA II trials, participants with relapsing multiple sclerosis (RMS) who received ocrelizumab for 5 years had less brain atrophy and confirmed disability progression that those who switched to ocrelizumab after 2 years of treatment with interferon beta-1a. Patients who began treatment with ocrelizumab 2 years earlier had significant reductions in 24-week confirmed disability progression compared to patients who switched from interferon beta-1a (16.1% vs 21.3% progression after 5 years, respectively; P = .014).

Click to continue reading on MD Magazine. 

Stay up to date on the latest news in specialty pharmacy by getting Specialty Pharmacy Times in your mailbox or inbox for free!

Click here to sign up for free for the bi-monthly Specialty Pharmacy Times print journal delivered to your address.

Click here to sign up for our email newsletters delivered every Monday, Wednesday, and Friday, in addition to breaking news alerts.

Click here to follow us on Facebook. 

Click here to follow us on Twitter. 

Click here to join our LinkedIn group. 

Related Articles

In a Specialty Pharmacy TimesĀ® Practice Pearls video series, expert panelists convened to discuss the challenges and best practices for dispensing multiple myeloma medications.
The use of digital technology and wireless communication systems has become more common in health care and has enabled patients to communicate important information about their vital signs, specific symptoms, and adherence to health care providers in multiple locations. Many patients with multiple sclerosis (MS) have expressed interest in the use of technology for their own self-management, including use of apps that help provide social support and self-management of their disease. Pharmacists need to understand the role of technology for patients with MS, including the use of smart auto-injectors as well as how innovative technology can be applied to improve health care decisions, improve adherence, and enhance engagement to improve patient outcomes. This program focuses on digital and mobile technology systems that are being utilized in patients with MS and explains how data may be applied for specific patient case- and population-based decisions.
New data show that higher exposure to ocrelizumab (Ocrevus, Genentech) correlated with lower B-cell levels and lower rates of disability progression.
Company Profile >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Contact Us
Terms & Conditions
MJH Associates >
Pharmacy Times
American Journal of Managed Care
MD Magazine
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2018
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.